Transgenic mouse with endogenous endoglin gene disruption
US6372958B1 · kind B1 · utility
3Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2000 |
| Grant date | Apr 16, 2002 |
| Priority date | — |
| Expiry date | May 25, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/0375
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Transgenic mice are genetically engineered for a deficiency in endoglin production. These mice may have a homozygous or hemizygous disruption of the endogenous endoglin gene. Homozygous mice exhibit a lack of endoglin production. The failure to produce endoglin results in arrested development of the vascular system of the mouse and no survival beyond E11.5. These mice and cells derived therefrom provide useful reagents for understanding the development and pathology of the mammalian vascular system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.